<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580241</url>
  </required_header>
  <id_info>
    <org_study_id>2606</org_study_id>
    <nct_id>NCT01580241</nct_id>
  </id_info>
  <brief_title>Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer</brief_title>
  <official_title>Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients
      with pancreatic cancer. The investigators would like to analyze its expression pre and post
      treatment, to gauge the correlation between current pancreatic cancer therapies and the
      expression of DCAMKL-1
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo surgical treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo chemotherapy treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo surgery followed by chemotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We
        will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy only,
        surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a change in
        DCAMKl-1 expression.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pancreatic cancer

        Exclusion Criteria:

          -  age &lt; 18, history of other types of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney Houchen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stephensen Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

